Sophie M. Ernst

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study.

Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: June 24, 2025

Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: towards more informative trials.

Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: towards more informative trials.

Journal: Nature reviews. Clinical oncology

Published: February 27, 2025

Connecting the dots: (RANKL+) extracellular vesicle count in blood plasma in relation to bone metastases, skeletal related events and osimertinib treatment in patients with EGFR mutated non-small cell lung cancer.

Connecting the dots: (RANKL+) extracellular vesicle count in blood plasma in relation to bone metastases, skeletal related events and osimertinib treatment in patients with EGFR mutated non-small cell lung cancer.

Journal: Translational lung cancer research

Published: October 25, 2024

A Response to the Letter to the Editor: Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib".

A Response to the Letter to the Editor: Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib".

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: July 04, 2024

Letter Regarding "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib".

Letter Regarding "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib".

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: June 13, 2024

Exploring the use of circulating tumor DNA for mutational signature analysis.

Exploring the use of circulating tumor DNA for mutational signature analysis.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: March 04, 2024

Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib.

Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: February 14, 2024

Lung Cancer in Brunei Darussalam.

Lung Cancer in Brunei Darussalam.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: February 02, 2024

Efficacy and Tolerability of Osimertinib and Sotorasib Combination Treatment for Osimertinib Resistance Caused by KRAS G12C Mutation: A Report of Two Cases.

Efficacy and Tolerability of Osimertinib and Sotorasib Combination Treatment for Osimertinib Resistance Caused by KRAS G12C Mutation: A Report of Two Cases.

Journal: JCO precision oncology

Published: December 14, 2023

Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis.

Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis.

Journal: EBioMedicine

Published: November 01, 2023

Factors associated with long-term antibody response after COVID-19 vaccination in patients treated with systemic treatment for solid tumors.

Factors associated with long-term antibody response after COVID-19 vaccination in patients treated with systemic treatment for solid tumors.

Journal: ESMO open

Published: June 08, 2023

Chemotherapy for patients with EGFR-mutated NSCLC after progression on EGFR-TKI's: Exploration of efficacy of unselected treatment in a multicenter cohort study.

Chemotherapy for patients with EGFR-mutated NSCLC after progression on EGFR-TKI's: Exploration of efficacy of unselected treatment in a multicenter cohort study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: March 15, 2023

Showing 1-12 of 17

Last Updated: 09/26/2026